Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

FDA Accepts Pfizer's Application for Hemophilia B Gene Therapy Fidanacogene Elaparvovec

Business Wire June 27, 2023

Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus

Business Wire June 26, 2023

FDA Approves Pfizer's LITFULO(TM) (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata

Business Wire June 23, 2023

Pfizer Declares Third-Quarter 2023 Dividend

Business Wire June 22, 2023

Pfizer's TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval

Business Wire June 20, 2023

Pfizer Invites Public to View and Listen to Webcast of August 1 Conference Call with Analysts

Business Wire June 20, 2023

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Business Wire June 6, 2023

Phase 3 Studies of Pfizer's Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options

Business Wire June 1, 2023

U.S. FDA Approves ABRYSVO(TM), Pfizer's Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults

Business Wire May 31, 2023

Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial

Business Wire May 30, 2023

Astellas Highlights Continued Delivery of Strong Cancer Portfolio and Pipeline at 2023 ASCO Annual Meeting

PR Newswire May 25, 2023

Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting

Business Wire May 25, 2023

Pfizer's PAXLOVID(TM) Receives FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19

Business Wire May 25, 2023

FDA Advisory Committee Votes in Support of Approval for Pfizer's Vaccine Candidate to Help Prevent RSV in Infants Through Maternal Immunization

Business Wire May 18, 2023

Pfizer Prices $31,000,000,000 Debt Offering

Business Wire May 16, 2023

IDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer to Support Registrational Trial Evaluating Darovasertib and Crizotinib Combination in First-Line Metastatic Uveal Melanoma

PR Newswire May 16, 2023

 Pfizer Announces Proposed Notes Offering

Business Wire May 15, 2023

Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress

GlobeNewswire May 8, 2023

Pfizer Reports First-Quarter 2023 Results

Business Wire May 2, 2023

XTANDI® (enzalutamide) plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide

PR Newswire April 29, 2023